Chemotherapy management for unfit patients with metastatic castration-resistant prostate cancer

• U. Anido-Herranz ^[2] ; N. Fernández-Núñez ^[3] ; J. Afonso-Afonso ^[4] ; L. Santomé-Couto ^[1] ; A. Medina-Colmenero ^[5] ; O. Fernández-Calvo ^[6] ; M. Lázaro-Quintela ^[7] ; S. Vázquez ^[3]
  1. [1] Hospital POVISA

     Hospital POVISA

     Vigo, España

     
  2. [2] Santiago University Hospital Complex (CHUS)
  3. [3] Lucus Augusti University Hospital (HULA )Lugo
  4. [4] El Ferrol University Hospital Complex (CHUF) Ferrol
  5. [5] Centro Oncológico de Galicia, A Coruña
  6. [6] Ourense University Hospital Complex
  7. [7] Vigo University Hospital Complex (CHUVI),Vigo

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 21, Nº. 3, 2019, págs. 249-258
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Administration of chemotherapy in prostate cancer depends on patient fitness. In unfit patients, physiological impairment determines the optimum treatment. Although no consensus on assessing patient fitness currently exists, this article proposes an algorithm combining the available information for administering chemotherapy, and in particular docetaxel, in unfit patients. It was constructed by reviewing factors that can influence treatment, such as performance status, taxane-related comorbidities and nutritional status. Geriatric scales for prostate cancer patients and alternative treatment regimens for this population are also reviewed. In summary, patients require overall assessment to optimise treatment. Use of docetaxel should be restricted in unfit patients, and other options must be evaluated, because of high toxicity and low efficacy.